Budget impact of gene therapy for sickle cell disease


What The Study Did:

This economic evaluation estimates the budget impact and affordability of a gene therapy for severe sickle cell disease from the perspective of U.S. Medicaid programs with the highest prevalence of sickle cell disease.


Authors:

Patrick DeMartino, M.D., of Oregon Health & Science University in Portland, is the corresponding author.


To access the embargoed study:

Visit our For The Media website at this link

https:/

/

media.

jamanetwork.

com/

(doi:10.1001/jamapediatrics.2020.7140)


Editor’s Note:

The article includes conflict of interest disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

###


Media advisory:

The full study and editorial are linked to this news release.


Embed this link to provide your readers free access to the full-text article

This link will be live at the embargo time

https:/

/

jamanetwork.

com/

journals/

jamapediatrics/

fullarticle/

10.

1001/

jamapediatrics.

2020.

7140?guestAccessKey=

eafaf224-0b11-42c0-888e-8b3555ec83fd&utm_source=

For_The_Media&utm_medium=

referral&utm_campaign=

ftm_links&utm_content=

tfl&utm_term=

032221

This part of information is sourced from https://www.eurekalert.org/pub_releases/2021-03/jn-bio031821.php

withyou android app